- Home
- BEAM
as 11-21-2024 12:31pm EST
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.9B | IPO Year: | 2020 |
| Target Price: | $45.90 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.84 - $49.50 | Next Earning Date: | 11-05-2024 |
| Revenue: | $349,643,000 | Revenue Growth: | 328.73% |
| Revenue Growth (this year): | -86.44% | Revenue Growth (next year): | 6.04% |
Stock Insider Trading Activity of Beam Therapeutics Inc. (BEAM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ciaramella Giuseppe | BEAM | President | Nov 6 '24 | Sell | $26.36 | 51,110 | $1,347,050.05 | 109,150 | |
| Ciaramella Giuseppe | BEAM | President | Oct 14 '24 | Sell | $26.27 | 51,110 | $1,342,751.70 | 109,150 | |
| Bellon Christine | BEAM | Chief Legal Officer | Oct 1 '24 | Sell | $23.48 | 385 | $9,039.57 | 104,209 | |
| Evans John M. | BEAM | CEO | Sep 30 '24 | Sell | $24.60 | 60,000 | $1,476,024.00 | 938,659 | |
| Cavanagh Bethany J | BEAM | SVP, Finance and Treasurer | Sep 30 '24 | Sell | $23.48 | 289 | $6,785.46 | 44,931 |
Latest Beam Therapeutics Inc. News
BEAM Breaking Stock News: Dive into BEAM Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
MT Newswires
13 days ago
Beam Therapeutics Insider Sold Shares Worth $1,347,050, According to a Recent SEC Filing
TipRanks
14 days ago
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink
MT Newswires
15 days ago
Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise
Zacks
15 days ago
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
MT Newswires
15 days ago
RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating
Simply Wall St.
15 days ago
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
MT Newswires
15 days ago
Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27
Compare BEAM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BEAM Beam Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.